For a long time clinicians have tried
standard methods of bone regeneration – osteosynthesis and osteoplasty –
when an absent bone part is replaced with allogenic, cadaveric or
demineralized bone matrix.
In the latter case cells and minerals are
removed from an animal bone tissue, and only the matrix is left – a
“bone-like sponge” that can be used to fill in defects in the bone to
stimulate formation of a new bone.
‘The combination of demineralized bone with gene therapy, is a promising solution for the currently existing complication problems in pseudarthrosis and other bone defects and fracture treatments.’
However, current procedures often
result in complications, such as resorption of the transplant. Parts of
the problem are poor blood supply and low levels of pro-osteogenic
A gene therapy drug that encodes
growth factors for the stimulation of blood vessel and bone formation has been created by a team headed by Professor Albert Rizvanov, director of the Gene and
Cell Technologies Open Lab.
The combination was highly effective in a patient admitted to the
Republican Clinical Hospital in Kazan, Russia. The treatment was
approved by the ethical committee, supported by the Ministry of
Healthcare of Tatarstan and published in BioNanoScience.
Professor Rizvanov explains, “We combined a demineralized bone
transplant with recombinant genetic material, which carries genes for
vascular endothelial growth factor, to stimulate new blood vessel growth
(angiogenesis), and bone morphogenetic protein to stimulate bone growth
(osteogenesis). Thus survival of transplant and bone tissue formation
was achieved at the desired location. We were able to translate our
basic and pre-clinical research and are the first to document the
efficacy of such therapy in a real clinical case of pseudarthrosis.”
Our therapy, a combination of demineralized bone with gene
therapy, is a promising solution for the currently existing complication
problems in pseudarthrosis and other bone defects and fracture
treatments. We now plan to offer such innovative treatments at the Kazan
University Clinic as a part of a new clinical trial program at
strategic academic unit Translational 7P Medicine for biomedical and